List of Contents

Generic Drugs Market Size, Share, and Trends 2024 to 2034

The global generic drugs market size accounted for USD 468.08 billion in 2025 and is forecasted to hit around USD 728.64 billion by 2034, representing a CAGR of 5.04% from 2025 to 2034. The North America market size was estimated at USD 173.79 billion in 2024 and is expanding at a CAGR of 5.17% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : March 2025
  • Report Code : 1205
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Generic Drugs Market 

5.1. COVID-19 Landscape: Generic Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Generic Drugs Market, By Drug Type

8.1. Generic Drugs Market Revenue and Volume, by Drug Type

8.1.1. Simple Generics

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Super Generics

8.1.2.1. Market Revenue and Volume Forecast

Chapter 9. Global Generic Drugs Market, By Brand

9.1. Generic Drugs Market Revenue and Volume, by Brand

9.1.1. Pure generic drugs

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Branded generic drugs

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Generic Drugs Market, By Route of Drug Administration 

10.1. Generic Drugs Market Revenue and Volume, by Route of Drug Administration

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Injection

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Cutaneous

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Generic Drugs Market, By Therapeutic Application

11.1. Generic Drugs Market Revenue and Volume, by Therapeutic Application

11.1.1. Central Nervous System (CNS)

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Cardiovascular

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Infectious Diseases

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Musculoskeletal Diseases

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Respiratory

11.1.5.1. Market Revenue and Volume Forecast

11.1.6. Oncology

11.1.6.1. Market Revenue and Volume Forecast

11.1.7. Others

11.1.7.1. Market Revenue and Volume Forecast

Chapter 12. Global Generic Drugs Market, By Distribution Channel

12.1. Generic Drugs Market Revenue and Volume, by Distribution Channel

12.1.1. Retail Pharmacy

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Hospital Pharmacy

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Online and Others

12.1.3.1. Market Revenue and Volume Forecast

Chapter 13. Global Generic Drugs Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Drug Type

13.1.2. Market Revenue and Volume Forecast, by Brand

13.1.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.1.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Drug Type

13.1.6.2. Market Revenue and Volume Forecast, by Brand

13.1.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.1.6.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Drug Type

13.1.7.2. Market Revenue and Volume Forecast, by Brand

13.1.7.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.1.7.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Drug Type

13.2.2. Market Revenue and Volume Forecast, by Brand

13.2.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.2.4. Market Revenue and Volume Forecast, by Therapeutic Application  

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Drug Type

13.2.6.2. Market Revenue and Volume Forecast, by Brand

13.2.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.2.7. Market Revenue and Volume Forecast, by Therapeutic Application  

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Drug Type

13.2.9.2. Market Revenue and Volume Forecast, by Brand

13.2.9.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.2.10. Market Revenue and Volume Forecast, by Therapeutic Application

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Drug Type

13.2.12.2. Market Revenue and Volume Forecast, by Brand

13.2.12.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.2.12.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Drug Type

13.2.14.2. Market Revenue and Volume Forecast, by Brand

13.2.14.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.2.14.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Drug Type

13.3.2. Market Revenue and Volume Forecast, by Brand

13.3.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.3.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Drug Type

13.3.6.2. Market Revenue and Volume Forecast, by Brand

13.3.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.3.6.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Drug Type

13.3.8.2. Market Revenue and Volume Forecast, by Brand

13.3.8.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.3.8.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Drug Type

13.3.10.2. Market Revenue and Volume Forecast, by Brand

13.3.10.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.3.10.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Drug Type

13.3.11.2. Market Revenue and Volume Forecast, by Brand

13.3.11.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.3.11.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Drug Type

13.4.2. Market Revenue and Volume Forecast, by Brand

13.4.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.4.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Drug Type

13.4.6.2. Market Revenue and Volume Forecast, by Brand

13.4.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.4.6.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Drug Type

13.4.8.2. Market Revenue and Volume Forecast, by Brand

13.4.8.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.4.8.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Drug Type

13.4.10.2. Market Revenue and Volume Forecast, by Brand

13.4.10.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.4.10.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Drug Type

13.4.11.2. Market Revenue and Volume Forecast, by Brand

13.4.11.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.4.11.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Drug Type

13.5.2. Market Revenue and Volume Forecast, by Brand

13.5.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.5.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Drug Type

13.5.6.2. Market Revenue and Volume Forecast, by Brand

13.5.6.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.5.6.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Drug Type

13.5.8.2. Market Revenue and Volume Forecast, by Brand

13.5.8.3. Market Revenue and Volume Forecast, by Route of Drug Administration

13.5.8.4. Market Revenue and Volume Forecast, by Therapeutic Application

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 14. Company Profiles

14.1. Mylan N.V.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Abbott Laboratories

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. ALLERGAN

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Teva Pharmaceutical Industries Ltd.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Eli Lilly and Company

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. STADA Arzneimittel AG

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. GlaxoSmithKline Plc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Baxter International Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Pfizer Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Sandoz International GmbH

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global generic drugs market size estimated at USD 445.62 billion in 2024 and is expected to hit around USD 728.64 billion by the end of 2034.

The low price of generic drugs as substitute to branded drugs is the supreme crucial factor in the growth of the global market for generic drugs.

The global generic drugs market is representing impressive CAGR of 5.04% during the forecast period 2025 to 2034.

In 2024, North America conquered the global market with a market share of more than 30%.

On the basis of drug type, simple generic drugs segment is expected hold largest revenue share in the forecast period of time 2025-2034. This growth is mostly attributed to low cost associated with the generic drugs over super generic drugs.

On the basis of therapeutic application, oncology therapeutic application segment accounted for the largest revenue with weighty share in 2024. This is attributed to increasing demand for the treatment of oncology disorders worldwide.

The key companies functioning in the worldwide generic drugs market are Mylan N.V. Abbott Laboratories, ALLERGAN, Teva Pharmaceutical Industries Ltd. Eli Lilly and Company, STADA Arzneimittel AG, GlaxoSmithKline Plc. Baxter International Inc. Pfizer Inc. Sandoz International GmbH among others.

Generic drugs refer to the drugs with a chemical make-up of a drug a like an existing branded drug. These medications are inexpensive and similar to branded drugs in power, and route of delivery, consistency, efficiency, and usage. These are subject to administration regulations in different nations, rather than associated with a particular company. These drugs are proven to be as safe and effective as their brand name formulation, which has already been marketed.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Plan your call and get expert insights!

Schedule a Meeting Schedule a Meeting

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us